2023

05/05/2023: Financial Information for the First Quarter of 2023

28/04/2023: Availability of the 2023 annual financial report French version

20/04/2023: 2022 Annuals Results

03/04/2023: Genomic Vision joins BioLead to advance innovation and production of biopharmaceuticals in France.

07/03/2023: Genomic Vision launches FiberSmart®, AI-powered software for automating genomic analysis

28/02/2023: Financial Information for the Fourth Quarter of 2022

20/01/2023: The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization

24/01/2023: Genomic Vision strengthens leadership team with the appointment of Frederic Hammel as Chief Operating Officer

13/01/2023: Bilan semestriel du contrat de liquidité contractée avec CM-CIC Securities. (Frenche version)

05/01/2023: Genomic Vision annonces succesful Beta Testing of FiberSmart^®

2022

22/12/2022: Our reflections on 2022 and what 2023 holds (Shareholders letter)

29/11/2022: Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research
Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer®

07/11/2022: Genomic Vision and Cambridge Consultants, Part of Capgemini, Announce the Development of an Innovative Technology Platform for In-depth Genomic Analysis

27/10/2022: Financial Information for the Third Quarter of 2022

24/10/2022: Genomic Vision: press release regarding changes in the Company’s governance

29/09/2022: First Half 2022 Results

22/07/2022: Financial information for the First Half of 2022

13/07/2022: Genomic Vision: changes in the Company’s governance

23/06/2022: Genomic Vision obtains the renewal of the ISO 13485: 2016 certification

16/06/2022: Genomic Vision granted a new patent for its “Physical Characterization of Telomeres” technique based on melecular combing.

08/06/2022: Mise à disposition des documents préparatoires et modalités de participation et de vote à l’AGO du 28 juin 2022. (French document, General Assembly part)

23/05/2022: Genomic Vision announces the approval by its Shareholders’ Meeting of all the resolutions supported by the Executive Board

20/05/2022: Genomic Vision Announces the Signing of an Addendum to the Contract Signed with Winance on April 11, 2022 for the Purpose of Implementing a New Financing Line, Subject to the Prior Approval of the Company’s Shareholders

05/05/2022: Financial Information for the First Quater of 2022.

02/05/2022: Availability of preparatory documents and participation and voting procedures for the extraordinary general meeting of shareholders on May 23, 2022. French documents (General Assembly part)

28/04/2022: Availability of the 2021 annual financial report French version

21/04/2022: Financial information: Annual Results 2021

11/04/2022: New Financing Line with Winance, Subject to Prior Approval of the Company’s Shareholders

17/02/2022: Genomic Vision’s technology is acquired by Department of Cell Biology, Microbiology & Molecular Biology at the University of South Florida to study mechanisms of DNA replication and replication stress

15/02/2022: Financial Information for the Fourth Quater of 2021

2021

24/12/2021: Financial information, 2 new tranches of convertible notes with warrants for 2M€

28/10/2021: Financial Information for the Third Quarter 2021

19/10/2021: Genomic Vision announces TeloSizer^® Triathlon program to provide academic researchers with an access path to molecular combing telomere services

13/10/2021: Appointment of Thierry Huet as R&D Director

28/09/2021: Genomic Vision launches TeloSizer^® for precise detection and quantitative measurement of telomere length

29/07/2021: First-half 2021 results 

22/07/2021: Genomic Vision expands its services offering to fulfill the demands for DNA replication analysis for drug discovery in cancer treatment.

16/06/2021: Issuance of 2 new tranches of convertible notes with warrants (OCABSA) for €2 million, as part of the financing line concluded with Winance for a maximum amount of €12 million

10/06/2021: 2^nd call for OGM on June 30, 2021 

17/05/2021: Financial Information for the First Quarter of 2021

14/05/2021: Partnership with SANOFI

29/04/2021: Financial information: Annual Results 2020 

14/04/2021: Appointment of Mark David Lynch as Global Commercial and Marketing Director

04/03/2021: Genomic Vision announces the issuance of the 2nd tranche of convertible notes with warrants (OCABSA) for €1.2 million, as part of the financing line concluded with Winance for a maximum amount of €12 million

18/02/2021: Financial Information for the Fourth Quarter of 2020

09/02/2021: Genomic Vision announces the availability of the prospectus relating to the financing program concluded with Winance for a maximum amount of €12 million

12/01/2021: French documentation “Bilan Semestriel du contrat de liquidité S2 2020”

2020

24/11/2020: Issuance of the first tranche of convertible notes with warrants (OCABSA)

12/11/2020: Financial Information for the Third Quarter of 2020

13/10/2020: Genomic Vision signs a distribution agreement for Covid-19 rapid diagnostic tests with Toda Pharma

29/09/2020: First Half Results

22/09/2020: Genomic Vision: convening of another Extraordinary General Meeting on October 30, 2020

10/08/2020: Genomic Vision announces the approval by its General Meeting of all the resolutions recommended by the Management Board

24/07/2020: Genomic Vision: convening of a new Combined Shareholders’ Meeting on August 10, 2020

20/07/2020: Financial Information for the First Half of 2020

09/07/2020: Half-yearly balance of the Liquidity Agreement with CM-CIC Securities

06/07/2020: Press release on the availability of the 2019 annual financial report

06/07/2020: Press release on the availability of the preparatory documents for the AGM of 24 July 2020

15/06/2020: Financial information: Implementation of a financing line via the reserved issuance of convertible notes with warrants (OCABSA) for a maximum of €12 million, subject to shareholders’ approval

29/05/2020: Financial information for the 1st quarter of 2020

21/05/2020: Financial information: FYR 2019

18/05/2020: Financial information : Drawdown of the 4th tranche

30/04/2020: Financial information

09/04/2020: Genomic Vision strenghtens its governance

13/02/2020: Dana Farber Cancer Institute adopts Genomic Vision’s platform including the FiberVisionS

11/02/2020: Financial information 

30/01/2020: Q4 2019 Financial information 

21/01/2020: Genomic Vision’s technology to be tested by the NIST

15/01/2020: Strategic Partnership between Genomic Vision and GIPTIS

2019

19/12/2019: Genomic Vision Technology Used to Genetically Characterise Patients Affected by Familial Adult Myoclonic Epilepsy (FAME)

30/10/2019: Q3 2019 Financial information 

21/10/2019: Promising results for the TLA assay

25/10/2019: Genomic Vision’s platform installed at the NIH

24/09/2019: Financial information for the First Half of 2019

06/08/2019: Molecular combing assay used to help physicians in the diagnostic of FSHD in more than 250 patients since its launch in China

26/07/2019: Financial information for the First Half of 2019: turnover and cash position

22/07/2019: Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)

09/07/2019: Genomic Vision reports of the Combined Shareholders’ Meeting of July 8, 2019

04/07/2019: Genomic Vision announces the acceptance notice of the second tranche of €1.0 million within the framework of the equity financing put in place with Winance

21/06/2019: Second convening of Shareholders meeting of July 8, 2019 

29/05/2019: Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 20 juin 2019 (in French)

02/05/2019: Financial information for the First Quarter of 2019

15/04/2019: Genomic Vision announces the drawdown of the first €1.5 million tranche within the framework of the equity financing put in place with Winance

26/03/2019: Genomic Vision announces the signing of the financing contract with Winance

06/03/2019: 2018 Annual Results

04/03/2019: The Extraordinary General Meeting of March 4, 2019: Genomic Vision shareholders approve the refinancing transaction with Winance to secure the development of the company until mid-2020

18/02/2019: Genomic Vision: convening of another Extraordinary Shareholders’ Meeting on March 4, 2019

08/02/2019: Genomic Vision: Oxford University selects the molecular combing technology to study DNA replication in the context of a rare disease

06/02/2019: Financial information for the Fourth Quarter of 2018

25/01/2019: Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Extraordinaire du 15 février 2019 (in French)

11/01/2019: Bilan semestriel du contrat de liquidités contracté avec CM-CIC Securities (in French)

11/01/2019: Genomic Vision announces the convening of an Extraordinary Shareholders’ Meeting on February 15, 2019, and provides an update on its financial situation

2018

10/12/2018: Genomic Vision: new preliminary results place HPV integration test as potential biomarker for prognosis of cervical cancer

22/11/2018: Genomic Vision signs a licensing agreement with Phyteneo on HPV integration test in Czech Republic

29/10/2018: Genomic Vision: positive results of the clinical study EXPL-HPV-002 in cervical cancer detection

24/10/2018: Financial information for the Third Quarter of 2018

28/09/2018: First Semester Financial Report 2018 (in French)

10/09/2018: Genomic Vision achieves second milestone with Quest Diagnostics on SMA carrier testing 

09/08/2018: Genomic Vision and European Equity Partners enter into agreement to use molecular combing as a genome integrity assay in the field of biomanufacturing 

06/08/2018: Genomic Vision: new perspectives in the genomic analysis of plants

25/07/2018: First half 2018 results

17/07/2018: Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)

05/07/2018: Genomic Vision provides an update on its commercial development and financial situation

19/06/2018: Compte rendu de l’assemblée générale mixte du 19 juin 2018 (in French)

11/06/2018: Genomic Vision: the performances of the FSHD diagnostic assay presented at the 2018 International FSHD Research Conference (IRC) in Las Vegas

29/05/2018: All documents for the shareholders’ meeting of June 19, 2018 are available on Genomic Vision website (in French only)

16/05/2018: Genomic Vision enters into a strategic research collaboration with Children’s Medical Research Institute (CMRI) on telomere length assay

02/05/2018: Genomic Vision invited to present molecular combing at Genopole

27/04/2018: Financial Information for the First Quarter of 2018

26/04/2018: Provision of the 2017 Financial Annual Report (in French only)

24/04/2018: Genomic Vision invited to present FiberVision platform at the Nist-FDA Genome Editing workshop in Gaithersburg (Maryland)

21/03/2018: 2017 Annual Results

14/03/2018: Genomic Vision extends its collaboration with Quest Diagnostics in spinal muscular atrophy (SMA)

17/01/2018: 2017 Annual revenue from sales: +36% to €2.1 million

04/01/2018: Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French only)

2017

19/12/2017: Genomic Vision optimizes the terms of its OCABSA (Convertible Notes with Warrants) financing line to obtain greater flexibility within the framework of its development

13/11/2017: All documents for the shareholders’ meeting of December 4, 2017 are available on Genomic Vision website (in French only)

24/10/2017: Financial information at Sept 30, 2017

19/10/2017: Genomic Vision signs a distribution agreement with AmCare Genomics Laboratory in China for its FSHD diagnostic assay

18/10/2017: Genomic Vision: report of the LSR R&D Day on october 16, 2017

11/10/2017: Genomic Vision presented the interim results of its clinical trial in cervical cancer screening at the Eurogin annual congress

03/10/2017: Genomic Vision hosts 2^nd R&D day on october 16^th in Paris

13/09/2017: High attendance at the first US satellite symposium on molecular combing

27/07/2017: Molecular combing featured in an oral presentation on CRISPR/Cas9 gene editing at the 3rd CSHL meeting in New York

25/07/2017: First half 2017 results

12/07/2017: The Cologne Center for Genetics (CCG), a major European core facility in genetic analyis, adopts the molecular combing technology

26/07/2017: Genomic Vision launches its online store “GV Store”

20/06/2017: Compte rendu de l’assemblée générale mixte du 20 juin 2017 (in French)

19/06/2017: Genomic Vision inks Chinese distribution deal with APG Bio Ltd

30/05/2017: All documents for the shareholders’ meeting of June 20, 2017 are available on Genomic Vision website (in French only)

30/05/2017: Genomic Vision declares its eligibility to the French tax regime PEA-PME for 2017/2018 (in French only)

22/05/2017: Genomic Vision to enter into technological collaboration with AstraZeneca in oncology

15/05/2017: Report of the IVD R&D Day of 10 May 2017

10/05/2017: Genomic Vision announces promising preliminary results for its clinical study in cervical cancer detection

09/05/2017: Financial information at March 31, 2017

20/04/2017: Genomic Vision hosts inaugural R&D day with its long-standing partner Quest Diagnostics

29/03/2017: Issuance of all the warrants for convertible notes with warrants (BEOCABSA) 

01/03/2017: 2016 annual results in line with the successful execution of the new strategy in LSR market

09/01/2017: Financial information at December 31st, 2016

2016

28/10/2016: Financial information at September 30, 2016 and implementation of a flexible financing via the reserved issuance of convertible notes with warrants

20/10/2016: Genomic Vision Presents the Initial Results of the Pilot Study Undertaken with Quest Diagnostics in Spinal Muscular Atrophy (SMA) at the ASHG 2016 Annual Meeting in Vancouver or the first half of 2016

26/07/2016: Results for the first half of 2016

20/07/2016: Genomic Vision is accelerating its clinical trial in cervical cancer with an additional study in the Czech Republic

11/07/2016: Genomic Vision launches EasyScan, the first digital service for analyzing DNA by molecular combing

16/06/2016: The clinical trial led by Genomic Vision and Reims University Hospital presented at the Eurogin Congress

09/05/2016: Financial information at March 31, 2016

23/03/2016: New strategic development area

22/03/2016: 2015 Annual Results

17/03/2016: Genomic Vision obtains NF EN ISO 13485:2012 quality certification

10/03/2016: Genomic Vision’s DNA analysis technology singled out in a study published by Nature

08/02/2016: Genomic Vision to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference

04/02/2016: 2016 Financial Calendar

18/01/2016: 2015 sales in line with expectations after all planned milestones with Quest Diagnostics were met

14/01/2016: Genomic Vision to demonstrate ‘molecular combing’ technology’s ability to identify novel cancer-causing BRCA gene variants

11/01/2016: Genomic Vision Expands its Senior Management Team through a Number of Strategic Recruitments

2015

14/12/2015: Genomic Vision and Reims University Hospital Launch Clinical Study to Establish New Screening Tool for Early Detection and Prevention of Cervical Cancer

03/12/2015: Genomic Vision signs a strategic partnership with the Imagine Institute, the largest European genetic research and care cluster

01/12/2015: GENOMIC VISION to Present at the LD Micro Main Event

12/11/2015: GENOMIC VISION to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

22/10/2015: Revenue from 3rd quarter activity up 47%

15/10/2015: GENOMIC VISION and ROUEN University Hospital launch a trial to improve genetic counseling for Infantile Spinal Muscular Atrophy in France

31/07/2015: 2015 first-half results in line with company expectations

09/06/2015: Genomic Vision selected for the Horizon 2020 program’s ‘BeyondSeq’ project with a total grant of €6 million

06/05/2015: Financial information of the 31st of March 2015 (French)

30/04/2015: 2014 Financial Report available (French)

31/03/2015: Genomic Vision reaffirms its eligibility for the PEA-SME status for 2015/2016 (French)

15/03/2015: 2014 annual results in line with the Company’s buoyant development (Total revenue from activity: €4.9 million | Operating costs under control | Solid cash position of €22.8 million)

17/02/2015: Genomic Vision renews its Strategic Collaboration with Quest Diagnostics for three more years

09/02/2015: Financial Agenda 2015

15/01/2015: 2014 Annual Revenue from Sales at €3.5 Million

07/01/2015: Genomic Vision achieves major milestone with delivery of new high-throughput genome analyzer to Quest Diagnostics